They already did issue such a release. It was one of the releases that I think has been criticized as being one of the Howell's. I thought then, and still do, that it was a very good release and I think it gained some traction. This dates back to Jan 7 of this year.
Noninvasive Test Will Provide Hope for 90% of Women Diagnosed With This Silent Killer
Press Release Source: Arrayit Corporation On Thursday January 7, 2010, 7:00 am EST
SUNNYVALE, CA--(Marketwire - 01/07/10) - On December 9th, 2009, Arrayit Corporation (OTC.BB:ARYC - News), a leading manufacturer of products and services for disease prevention, treatment and cure, announced a breakthrough in ovarian cancer screening utilizing a microarray-based diagnostic test that will detect whether a patient is pre-symptomatic for this silent killer.
In a report by NBC's Dr. Robert Bezell on Tuesday, January 5th, it was reported that although research continues, there is no effective screening test currently available to detect the pre-symptomatic presence of ovarian cancer. The report missed the mark, which indicates that press information distributed by Arrayit on December 9th, somehow fell through the cracks. The fact is, Arrayit's advanced screening test, OvaDx(TM), will be available very soon.
Researchers at a major cancer research institute have worked for six years to identify more than 100 biomarkers unique to ovarian cancer. The proteomic markers were finally identified using a novel and patented microarray platform created by Arrayit. A noninvasive screening test can be performed via a simple blood test that can be conducted during annual physical exams. The test will soon be submitted to the FDA for approval, and since it is an in vitro diagnostic multivariate index assay, prompt approval is anticipated.
According to the American Cancer Society, more than 21,500 women will be diagnosed with Ovarian Cancer this year, and 14,000 will die. Up until now, screening tests could only detect the 'Silent Killer' when the disease is symptomatic, meaning the disease has progressed to stage 3 or 4. Unfortunately at this late stage of detection the cancer most certainly has metastasized and spread beyond the ovary, which proves fatal for 75% of women diagnosed.
Ovarian cancer ranks fifth in cancer deaths among women, accounting for more deaths than any other cancer of the female reproductive system. Clinicians state that the primary reasons for such a high fatality rate are that there are no discernable early symptoms, and there has not been an effective early detection test available. The American Cancer Society estimates that 90% of woman diagnosed with ovarian cancer could survive with early detection. Currently only 20% of women diagnosed are in the early stages.
The early detection of ovarian cancer holds tremendous potential to profoundly impact the quality of life of ovarian cancer victims and shift costs from treatment to detection ensuring survivability for a larger population. Upon FDA approval, OvaDx(TM) will be marketed and sold by Arrayit Corporation's subsidiary, Arrayit Diagnostics (Ovarian), Inc., in Houston, Texas under a licensing agreement.
About Arrayit
Arrayit Corporation (OTC.BB:ARYC - News), headquartered in Sunnyvale, California, leads and empowers the genetic, research, pharmaceutical, and diagnostic communities through the discovery, development and manufacture of proprietary life science technologies and consumables for disease prevention, treatment and cure. Arrayit now offers over 650 products to a customer base of more than 10,000 clinics and research facilities, and more than 5,000 laboratories worldwide, including most every major university, pharmaceutical and biotech company, major agricultural and chemical company, government agency, national research foundation and many private sector enterprises. Please visit www.arrayit.com for more information.
Market Data 
Markets 
AI
